Colorectal liver metastasis: molecular mechanism and interventional therapy

H Zhou, Z Liu, Y Wang, X Wen, EH Amador… - Signal transduction and …, 2022 - nature.com
Colorectal cancer (CRC) is one of the most frequently occurring malignancy tumors with a
high morbidity additionally, CRC patients may develop liver metastasis, which is the major …

Immunotherapy in melanoma: recent advances and future directions

A Knight, L Karapetyan, JM Kirkwood - Cancers, 2023 - mdpi.com
Simple Summary Immunotherapy has demonstrated the ability to reduce the risk of
recurrence for melanoma following surgical resection and improve survival in patients with …

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3 …

GV Long, R Dummer, O Hamid, TF Gajewski… - The Lancet …, 2019 - thelancet.com
Background Immunotherapy combination treatments can improve patient outcomes.
Epacadostat, an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed …

Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy

TN Gide, C Quek, AM Menzies, AT Tasker, P Shang… - Cancer cell, 2019 - cell.com
Cancer immunotherapies provide survival benefits in responding patients, but many patients
fail to respond. Identifying the biology of treatment response and resistance are a priority to …

Biomarkers of response to PD-1 pathway blockade

H Li, PA van der Merwe, S Sivakumar - British Journal of Cancer, 2022 - nature.com
The binding of T cell immune checkpoint proteins programmed death 1 (PD-1) and cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4) to their ligands allows immune evasion by …

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

F Bensch, EL van der Veen, MN Lub-de Hooge… - Nature medicine, 2018 - nature.com
Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) blockade is effective in a subset of
patients with several tumor types, but predicting patient benefit using approved diagnostics …

Primary, adaptive, and acquired resistance to cancer immunotherapy

P Sharma, S Hu-Lieskovan, JA Wargo, A Ribas - Cell, 2017 - cell.com
Cancer immunotherapy can induce long lasting responses in patients with metastatic
cancers of a wide range of histologies. Broadening the clinical applicability of these …

Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation

EC Paver, WA Cooper, AJ Colebatch, PM Ferguson… - Pathology, 2021 - Elsevier
Immunotherapy with checkpoint inhibitors is well established as an effective treatment for
non-small cell lung cancer and melanoma. The list of approved indications for treatment with …

PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer

JH Yearley, C Gibson, NI Yu, C Moon, E Murphy… - Clinical cancer …, 2017 - AACR
Abstract Purpose: Tumor-associated PD-L1 expression is predictive of clinical response to
PD-1–directed immunotherapy. However, PD-L1–negative patients may also respond to PD …

Pembrolizumab versus ipilimumab in advanced melanoma

C Robert, J Schachter, GV Long… - … England Journal of …, 2015 - Mass Medical Soc
Background The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment
for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 …